Indication
For the treatment of flares in adult patients with generalised pustular psoriasis (GPP) as monotherapy.
Medicine details
- Medicine name:
- spesolimab (Spevigo)
- SMC ID:
- SMC2729
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Skin
- Submission type
- Full
- Publication due date:
- 10 March 2025
- SMC meeting date:
- 04 February 2025
- Patient group submission deadline:
- 02 December 2024